Popular Articles

NEWSALERT: GlaxoSmithkline Consumer Healthcare posts 20% rise in Q1 profit
The healthcare major GlaxoSmithkline Consumer Healthcare Ltd has posted 19.56 per cent rise in net profit at Rs 55.19 crore for the quarter ended June 30, 2009 as compared to Rs 46.16 crore in the corresponding quarter last year.

Religare plans $500-million pan-Asia fund
After venturing into the private equity (PE) space earlier through a joint venture, financial services provider Religare is now planning to go solo.

News of the day

Auction those mines
Business Standard / New Delhi November 17, 2009, 0:10 IST
Small Business

Sanofi bags order from US for supplying swine flu vaccine

Sanofi Pasteur, the vaccine division of Sanofi-Aventis Group on Monday said it has received order from the US Department of Health and Human Services (HHS) to supply antigen for 27.3 million doses of Influenza A (H1N1) 2009 monovalent vaccine for swine flu. - Founder may sell stake - Sanofi Pasteur buys majority stake in Shantha Bio - "H1N1 virus has not mutated, vaccines on track" - US body to work with Andhra govt - Works still incomplete on Dasara eve - Obama announces plan to expand fight against swine flu "The new order is for the production of bulk antigen equivalent to 27.3 million doses based on 15 mcg of antigen per dose. Specifications for formulation and filling of this new bulk order will be the subject of a separate order," Sanofi Pasteur said in a statement. Till date, Sanofi Pasteur has committed a total of 75.3 million doses of Influenza A(H1N1) 2009 Monovalent Vaccine to the US government, it added. Antigen is the basic raw material for producing any vaccines.Sanofi Pasteur had begun the commercial production of the new influenza vaccine in June using the novel virus strain to provide doses for clinical trials and to respond to the initial order from HHS. Influenza A (H1N1) 2009 Monovalent Vaccine was licensed by the US health regulator Food and Drug Administration on September 15, 2009. The company has two facilities- one each in US and France for producing the vaccines and it would supply the vaccine to HHS using its US-based production facility.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):